Cardenas Victor J, Seashore Justin B, Tapryal Nisha, Ameri Moe, Rivera Rosalinda, Sharma Kabir, Hazra Tapas
University of Texas Medical Branch.
Kaiser Permanente Northern California, Vacaville Medical Center.
Res Sq. 2024 Sep 3:rs.3.rs-4849668. doi: 10.21203/rs.3.rs-4849668/v1.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway disease that is an independent risk factor for lung cancer. NEIL2, a DNA glycolase involved in DNA repair during transcription, has also been associated with an increased incidence of malignancies in humans. NEIL2 knockout mouse models have demonstrated increased inflammation and oxidative DNA damage in the lungs after exposure to an inflammatory insult, but data are lacking regarding NEIL2 function in individuals with stable COPD and during severe acute exacerbations of COPD (AECOPD). We investigated whether NEIL2 levels and oxidative DNA damage to the transcribed genome are altered in individuals with stable COPD and AECOPD.
The study was conducted at a single center in the US. Eligible subjects underwent a one-time 30 cc venous blood draw. The population consisted of 50 adults: 16 with stable COPD, 11 hospitalized for AECOPD, and 23 volunteers. We analyzed blood leukocytes for NEIL2 mRNA and DNA damage by RT-qPCR and LA-qPCR, respectively, in all groups. Plasma levels of seven biomarkers, CXCL1, CXCL8, CXCL9, CXCL10, CCL2, CCL11 and IL-6, were analyzed in the COPD groups using a magnetic bead panel (Millipore).
The NEIL2 mRNA levels were lower in individuals with stable COPD and AECOPD than in controls (0.72 for COPD, p = 0.0289; 0.407 for AECOPD, p = 0.0002). The difference in NEIL2 mRNA expression between the stable COPD group and AECOPD group was also statistically significant (p < 0.001). The fold change in DNA lesions per 10 kb of DNA was greater in the stable COPD (9.38, p < 0.0008) and AECOPD (15.81, p < 0.0004) groups than in the control group. The difference in fold change was also greater in the AECOPD group versus stable COPD p < 0.0236). Biomarker levels were not significantly different between the COPD groups. NEIL2 levels were correlated with plasma eosinophil levels in the stable COPD group (r = 0.737, p < 0.0027).
NEIL2 mRNA levels are significantly reduced in COPD subjects and are associated with increased DNA damage and inflammation. These results reveal a mechanism that promotes persistent airway inflammation and oxidative genomic damage and increases the risk of malignancy in this population.
慢性阻塞性肺疾病(COPD)是一种慢性炎症性气道疾病,是肺癌的独立危险因素。NEIL2是一种参与转录过程中DNA修复的DNA糖基化酶,也与人类恶性肿瘤发病率增加有关。NEIL2基因敲除小鼠模型显示,在暴露于炎性刺激后,肺部炎症和氧化性DNA损伤增加,但关于NEIL2在稳定期COPD患者和COPD严重急性加重期(AECOPD)患者中的功能,数据尚缺乏。我们研究了稳定期COPD患者和AECOPD患者中NEIL2水平及转录基因组的氧化性DNA损伤是否发生改变。
该研究在美国的一个单一中心进行。符合条件的受试者接受一次30毫升静脉血采集。研究人群包括50名成年人:16名稳定期COPD患者、11名因AECOPD住院的患者和23名志愿者。我们分别通过逆转录定量聚合酶链反应(RT-qPCR)和连接酶检测反应定量聚合酶链反应(LA-qPCR)分析了所有组血液白细胞中的NEIL2 mRNA和DNA损伤情况。使用磁珠检测板(密理博公司)分析了COPD组中7种生物标志物(CXCL1、CXCL8、CXCL9、CXCL10、CCL2、CCL11和IL-6)的血浆水平。
稳定期COPD患者和AECOPD患者的NEIL2 mRNA水平低于对照组(COPD患者为0.72,p = 0.0289;AECOPD患者为0.407,p = 0.0002)。稳定期COPD组和AECOPD组之间NEIL2 mRNA表达的差异也具有统计学意义(p < 0.001)。每10 kb DNA的DNA损伤倍数变化在稳定期COPD组(9.38,p < 0.0008)和AECOPD组(15.81,p < 0.0004)中高于对照组。AECOPD组与稳定期COPD组之间的倍数变化差异也更大(p < 0.0236)。COPD组之间的生物标志物水平无显著差异。稳定期COPD组中NEIL2水平与血浆嗜酸性粒细胞水平相关(r = 0.737,p < 0.0027)。
COPD患者的NEIL2 mRNA水平显著降低,并与DNA损伤增加和炎症相关。这些结果揭示了一种促进持续性气道炎症和氧化性基因组损伤并增加该人群恶性肿瘤风险的机制。